Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Serotonin, SSRIs, and Sexual Dysfunction

Mechanism of SSRI anorgasmia/low libido and the contested PSSD syndrome

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable, describes side effects of approved SSRIs; PSSD recognized by EMA (2019) as a possible persistent effect

Reference only. Not medical advice.

What can go wrong

SSRI-induced sexual dysfunction is common, often under-discussed, and can drive non-adherence; it usually but not always resolves on discontinuation. PSSD, if it occurs, can be persistent and distressing with no proven cure, a genuine reason for informed consent before starting SSRIs, especially in younger patients. However, untreated depression and anxiety themselves impair sexual function, so stopping or avoiding antidepressants on PSSD fears alone can be harmful. Medication changes must be made with a prescriber; abrupt SSRI cessation risks discontinuation syndrome.

This is something to take to a clinician. The Atlas can tell you what is known about serotonin, ssris, and sexual dysfunction in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Serotonin is the principal inhibitory neurotransmitter of male sexual response, and SSRIs, by raising synaptic serotonin, commonly cause delayed orgasm, anorgasmia, reduced libido, and erectile difficulty; rates of treatment-emergent sexual dysfunction in prospective studies often reach 40-70%, far above what early trials reported. The mechanism centrally involves serotonergic suppression of dopamine and excessive 5-HT2C/5-HT2A signaling, with peripheral and nitric-oxide effects as well. Post-SSRI sexual dysfunction (PSSD), persistent dysfunction continuing after the drug is stopped, is a contested but increasingly recognized syndrome; the European Medicines Agency acknowledged in 2019 that sexual dysfunction may persist after discontinuation.

The brain's brake on sex, and the drugs that press it, sometimes permanently.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Explaining antidepressant-associated sexual side effects
  • Therapeutic delay of ejaculation in premature ejaculation
  • Framing the PSSD safety signal

How it works

Elevated serotonin inhibits sexual function through several routes: stimulation of 5-HT2C and 5-HT2A receptors suppresses mesolimbic and hypothalamic dopamine, dampening desire and arousal; serotonergic tone from the raphe and nucleus paragigantocellularis inhibits the spinal ejaculation generator (the basis for using SSRIs and dapoxetine to delay ejaculation); and peripheral/nitric-oxide effects may impair erection and genital sensation. Agents that spare or counteract this, bupropion (dopaminergic/noradrenergic), mirtazapine, and the 5-HT1A agonism of vilazodone/vortioxetine, tend to cause less sexual dysfunction.

PSSD, the contested persistence

PSSD refers to sexual dysfunction, genital anhedonia or numbness, low libido, ejaculatory/orgasmic failure, that begins with SSRI/SNRI use and persists for months or years after stopping. It is documented through case series (Healy and colleagues, Ben-Sheetrit, Reisman) and the Reddit/community-reported literature, and the EMA's PRAC concluded in 2019 that persistent sexual dysfunction warrants product-information mention. But there is no validated diagnostic test, no established prevalence, no proven mechanism (proposed: epigenetic, downregulated 5-HT receptor signaling, neurosteroid changes, peripheral neuropathy), and no proven treatment. It remains genuinely contested: real enough for a regulator to flag, under-characterized enough that rigorous prospective data are largely absent.

Safety in detail

Antidepressant changes must be made with a prescribing clinician; abrupt SSRI cessation can cause discontinuation syndrome and untreated depression carries its own risks. PSSD has no proven treatment.

What people get wrong

  • Often saidSSRI sexual side effects are rare

    ActuallyEarly trials understated them because they relied on spontaneous reporting; prospective direct questioning finds rates of ~40-70%. They are common, not rare.

  • Often saidPSSD is proven to be a defined disease with a known cause and cure

    ActuallyPSSD is a recognized safety signal (EMA 2019) supported by case series, but it lacks a validated definition, established prevalence, proven mechanism, or proven treatment. It is real enough to flag and uncertain enough to remain contested.

  • Often saidYou should stop your antidepressant to avoid sexual side effects

    ActuallyDepression and anxiety themselves impair sexual function, and abrupt cessation is risky. Switching agents (e.g., to bupropion) or adjunct strategies are decisions for a prescriber.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

SSRIs entered wide use after fluoxetine's 1987 launch, and their sexual side effects were initially minimized in registration trials. Montejo's 2001 prospective work exposed how common they truly were. Through the 2000s-2010s, clinicians and patients reported dysfunction persisting after discontinuation; David Healy became a leading advocate for recognizing PSSD. The EMA's 2019 PRAC conclusion marked the first major regulatory acknowledgement that the effect can persist.

  1. 1987Fluoxetine launched; SSRI era begins
  2. 1998SSRIs formally studied to delay ejaculation in PE
  3. 2001Montejo prospective data reveal high true rates of sexual dysfunction
  4. 2006Dapoxetine developed as on-demand SSRI for PE
  5. 2018-2020Healy et al. case series advance PSSD recognition
  6. 2019EMA PRAC concludes sexual dysfunction may persist after SSRI discontinuation

At a glance

Treatment-emergent SSRI sexual dysfunction
~40-70% in prospective studies
Core symptoms
Delayed/absent orgasm, low libido, ED, genital numbness
EMA acknowledgement of PSSD
2019 (label-relevant signal that effects may persist)
Therapeutic exploitation
SSRIs/dapoxetine used to delay ejaculation in PE

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Serotonin, SSRIs, and Sexual Dysfunction. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Montejo et al., prospective SSRI sexual dysfunction2001

    Found treatment-emergent sexual dysfunction in roughly 59% of patients on SSRIs when assessed by direct questioning, far exceeding spontaneous-report rates

  • Healy et al., enduring sexual dysfunction after SSRIs/PSSD2018-2020

    Compiled case series characterizing PSSD and argued for its recognition as a distinct iatrogenic syndrome

  • EMA PRAC review2019

    Concluded that sexual dysfunction may persist after discontinuation of SSRIs/SNRIs and should be reflected in product information

  • Waldinger et al., SSRIs for premature ejaculation1998 onward

    Established the therapeutic use of serotonergic delay of ejaculation, underpinning dapoxetine's development